12 results about "Biodistribution" patented technology

The near-infrared window of fluorescent heptamethine cyanine dyes greatly facilitates biological imaging because there is deep penetration of the light and negligible background fluorescence. But dye instability, aggregation, and poor pharmacokinetics are current drawbacks that limit performance and the scope of possible applications. All these limitations are simultaneously overcome with a new molecular design strategy that produces a charge balanced and sterically shielded fluorochrome. The key design feature is a meso-Aryl group that simultaneously projects two shielding arms directly over each face of a linear heptamethine polyene. Cell and mouse imaging experiments compared a shielded heptamethine cyanine dye (and several peptide and antibody bioconjugates) to benchmark heptamethine dyes and found that the shielded systems possess an unsurpassed combination of photophysical, physiochemical and biodistribution properties that greatly enhance bioimaging performance.

Aspects of the invention provide an AAV product that delivers an FXN gene supplementation or replacement strategy throughout the human CNS and heart at levels of DNA biodistribution, RNA expression, and FXN protein levels expected to restore function in Friedrich's ataxia patients.

Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and / or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

The present invention relates to near-infrared fluorescent heptamethine dyes and conjugates of heptamethine dyes with favourable biodistribution and bleaching properties.

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and / or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

The present disclosure provides a compound of formula (I) [Formula 1] TIFF2026500338000155.tif27165 or a pharmaceutically acceptable salt thereof, and uses thereof, for example, in assessing the biodistribution and / or concentration of a biomolecule in a subject.

The present invention relates to compounds comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib), each comprising an N-terminal modification group A comprising a biodistribution modulator, where the N-terminal modification group A is linked to Xaa1, and each comprising a C-terminal group C-terminal comprising a biodistribution modulator, where the C-terminal group C-terminal is linked to Xaa11. (Ia) and (Ib).

Antibodies having enhanced biodistribution and / or pharmacokinetics obtained through conjugation of a negatively charged organic moiety are provided. Also provided are methods of enhancing the biodistribution and / or pharmacokinetics of an antibody. The enhanced antibodies find use in immunotherapy, radiotherapy, and in vivo imaging.

The present application relates to a method for improving the accuracy of in vivo cell tracking using iron chelators, comprising the following steps: S1, preparing drug materials; S2, preparing animals and cells: preparing bone marrow cells, S3, removing free iron chelators in vivo 89 Zr and 68 Ga, S4, radiolabeling mesenchymal stem cells and bone marrow cells; S5, performing Micro-PET imaging: S6, performing Micro-PET imaging data processing and analysis: S7, in vitro biodistribution; S8, performing pharmacokinetic studies; S9, extracting hAlu genomic DNA and performing qPCR detection; S10, establishing a standard curve of cell number and cycle threshold; S11, performing absorbed dose estimation; S12, performing in vitro cell experiments; S13, final statistical analysis. The present application provides a method for improving the accuracy of in vivo cell tracking using iron chelators, which realizes the effect of removing free radioactive metal ions in vivo using iron chelators, and ensures the accuracy of in vivo tracking labeled cells.

Methods are disclosed for electronically labeling and systemically administering radiotracers for targeted diagnostic and therapeutic applications, including immunomodulation. Radiotracers are electronically radiolabeled via direct application to a conductive conductor and delivered systemically through trans-vascular absorption, enabling controlled biodistribution confined to the conductor contact and minimizing off-target exposure. Real-time imaging permits monitoring of radiotracer distribution and activity during administration. Applications include immune modulation for suppression, ablation, or stimulation, as well as activation of non-radioactive precursors for diagnostic and therapeutic use. These methods are applicable to cancer, infectious disease, and autoimmune disorder treatment. Parameters such as radiotracer choice, radioactive activity, precursor formulation, dosing schedule, and administration duration may be adjusted individually or in combination to achieve the desired outcome. These techniques provide reproducible, controllable radiotracer delivery suitable for both imaging and therapy with integrated monitoring.

The present invention relates to fibronectin-binding peptides according to the sequenceFnI5BS-L1-FnI4BS-L2-FnI3BS-L3-FnI2BSwhich are useful in tumor or fibrosis diagnosis and therapy. Instant peptides show improved fibronectin-binding and biodistribution properties compared to the prior art. Furthermore, instant peptides may be conjugated to a payload and are useful in the treatment and / or prevention of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis. Instant peptides are also useful in diagnosis of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis.